

Paris, October 8, 2018

Truffle Capital announces exclusive and global License Agreement between Yale University and its newly created French start-up Nanosive

Nanosive, a portfolio BioMedTech company of the venture capital firm Truffle Capital, gets access to a radically innovative technological platform of encapsulation of active compounds, with promising applications in dermo-cosmetics

Second license agreement within a few months between one of the top US universities and Truffle Capital to create in France a BioMedTech start-up

Paris, October 8, 2018 - Truffle Capital, an independent venture capital firm focused on creating and financing start-ups with disruptive technologies in life sciences and information technology, has announced the signature of an exclusive and global License Agreement between Yale University and Truffle Capital's newly created start-up company Nanosive SAS, whose operations will be based in Marseille, France. Truffle Capital invested in Nanosive through its new *Truffle BioMedTech Fund* which has already collected \$102 million and its *Truffle Innove FRR France* fund.

With this License Agreement, Nanosive acquires the worldwide and exclusive rights to develop and exploit a technological platform for a wide range of applications in dermo-cosmetics, in particular sun protection, the prevention of cancer and aging of the skin. There is a growing consumer demand for safer sunscreens offering a high protection and compatible with daily use.

The technology is based on an innovative process of encapsulation of actives in polymers which present remarkable properties of adhesiveness. It was developed at Yale University in the laboratories of Prof. W. Mark Saltzman, Goizueta Foundation Professor of Chemical and Biomedical Engineering, and Prof. Michael Girardi MD, ViceChairman, and Program Director at the Department of Dermatology,. Prof. Saltzman and Prof. Girardi as scientific co-founders of Nanosive will co-chair its Scientific Advisory Board and will lead sponsored research programs for the company in their laboratories. *"We are excited about working with Truffle Capital and this opportunity to advance our photoprotection technology,"* said Prof. Saltzman. *"This partnership will allow us to develop our novel strategies for the safe and effective prevention of skin cancer, as well as the prevention of changes associated with photoaging,"* added Michael Girardi.

Philippe Pouletty, MD, co-founder and CEO of Truffle Capital and Chairman of Nanosive, and his Truffle Capital partners Antoine Pau, Alain Chevallier and Vincent Gardès, said: *"This agreement represents a new achievement in the deployment of our Truffle BioMedTech Fund strategy which is to source disruptive technologies worldwide in the best universities to build BioMedTech start-ups in France."*

John Puziss, PhD, Director of Business Development in the Office of Cooperative Research at Yale, added: *“We are delighted to partner with Truffle Capital in launching Nanosive, and we look forward to working together to develop this important technology.”*

This is the second license agreement within a few months between a new France-based Truffle start-up company and one of the top 10 US universities.

Nanosive operations will be located in the newly created Obratori incubator of L’Occitane Group, in Marseille, France.

About Truffle Capital

Founded in 2001, Truffle Capital is an independent, European venture capital firm focused on disruptive technologies in life sciences (BioTech and MedTech) and IT (FinTech and InsurTech). Truffle Capital aims to support the creation and growth of young innovative companies with the potential to become tomorrow’s market leaders. Chaired by Patrick Kron, alongside the company’s founders and CEOs, Philippe Pouletty, M.D. and Bernard-Louis Roques, Truffle Capital currently manages €450M (close to €1 billion since inception) and has supported over 80 companies since its creation, in the digital technologies and life sciences sectors. At the end of 2017, Truffle Capital successfully completed the first close of its two new institutional funds, Truffle Financial Innovation Fund¹ and Truffle BioMedTech Crossover Fund², as well as the first close of a fund dedicated to the French Reserve Fund (Fonds de Réserve pour les Retraites ou FRR).

Find out more: www.truffle.com – Twitter: [@trufflecapital](https://twitter.com/trufflecapital)

Press contact

ALIZE RP

Caroline Carmagnol and Aurore Gangloff

truffle@alizerp.com

+33 (0) 1 44 54 36 66 / +33 (0) 6 64 18 99 59

¹ See press release distributed, November 16, 2017: <http://www.truffle.com/wp-content/uploads/2017/11/CP-Truffle1erClosingFinTech-16-11-2017.pdf> (French only)

² See press release distributed, January 10, 2018: http://truffle.com/wp-content/uploads/2018/01/PR_BioMed_Vdef.pdf